Skip to main content
European Commission logo print header

BIOengineered grafts for Cartilage Healing In Patients (BIO-CHIP)

Descripción del proyecto

Avance esperanzador en la regeneración del cartílago

Las lesiones del cartílago articular pueden provocar artrosis y los tratamientos actuales no logran restaurar con eficacia la estructura ni la función del cartílago. Ello representa un problema serio para millones de personas de todo el mundo. En este contexto, el equipo del proyecto BIO-CHIP, financiado con fondos europeos, está elaborando un ensayo clínico de fase II para probar la capacidad de los injertos de ingeniería basados en condrocitos nasales (CN) autógenos para inducir la regeneración del cartílago. En concreto, el objetivo en el proyecto es definir el grado de maduración necesario para los injertos basados en CN y ampliar la variedad de indicaciones clínicas para las lesiones previas a la artrosis. La solución de BIO-CHIP ofrecerá esperanza a quienes requieren una regeneración del cartílago y podría generar importantes beneficios terapéuticos y comerciales.

Objetivo

Spontaneous healing of articular cartilage injuries is poor and untreated defects predispose to osteoarthritis. Current therapies, including innovative autologous cell-based treatments, cannot predictably and reproducibly restore cartilage structure and function.
BIOCHIP will carry out a multicenter, prospective phase II clinical trial to treat knee cartilage injuries using engineered grafts based on autologous nasal chondrocytes (NC). As compared to typically employed articular chondrocytes, NC have a higher and more reproducible capacity to generate mature cartilage tissues. Importantly, molecular/mechanical characterization, large size animal studies and a phase I trial carried out by BIOCHIP partners have already shown the compatibility of NC upon implantation in a joint, with promising preliminary clinical results.
BIO-CHIP’s specific objectives are:
(1) To test the hypothesis that the maturation of NC-based cartilage grafts improves the clinical efficacy in the treatment of cartilage lesions (108 patients will be recruited to reach statistical significance)
(2) To extend the range of clinical indications of NC-based grafts to so far untreatable pre-osteoarthritic lesions (‘kissing’ cartilage lesions in a sheep model)
BIO-CHIP capitalizes on clinical experience of 4 reference centers for cartilage surgery, on established GMP manufacturing capacity and on preparation for commercial exploitation by a strong orthopedic device company. Demonstration of therapeutic efficacy of the new treatment will address a large clinical need (over 2 million cartilage defects/year worldwide), improve quality of life (reduce pain & disability in the young, delay prosthetic implants in the elderly), exploit a commercial opportunity (prospected revenues of up to 130 million €/year) and reduce healthcare costs (estimated 12,000€ healthcare savings/procedure). BIO-CHIP will consolidate the currently leading role of Europe in the development of cell-based cartilage regeneration strate

Convocatoria de propuestas

H2020-PHC-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-PHC-2015-single-stage_RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

UNIVERSITAT BASEL
Aportación neta de la UEn
€ 0,00
Dirección
PETERSPLATZ 1
4051 Basel
Suiza

Ver en el mapa

Región
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 510 187,50

Participantes (12)